Trial Profile
Phase II study of weekly amrubicin in patients with refractory or relapsed non-small cell lung cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Aug 2015
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 02 Oct 2009 New trial record